Contact Us
Contact Us
Contact Us

Prof. Didier Blaise joins Clinical Advisory Board

Race is pleased to announce the appointment of Professor Didier Blaise to the Clinical Advisory Board (CAB).

Mr Blaise is Professor of Medicine at the Aix-Marseille University in Marseille, France and has a number of additional prestigious appointments (see ‘Detailed background Prof. Didier Blaise’). He has conducted numerous national and international clinical trials in the field of hematopoietic stem cell transplantation and oncology and is the author of more than 500 peer reviewed papers in the field of haematology oncology.

Along with Prof. Jaap Boelens and under the leadership of Prof. Borje Andersson, Prof. Blaise will play a critical role in the implementation of RAC’s 5-Path clinical strategy.

CAB Chairman Prof. Borje Andersson’s response was enthusiastic:
“It is with utmost pleasure and excitement that I welcome Professor Blaise to the Race Oncology Clinical Advisory Board. His expertise in clinical haematology and pharmacology as well immunology, paired with his deep, first-hand knowledge of all facets of the problems facing clinical oncologists will be extremely important in complementing the existing expertise of our team. We anticipate his contributions to significantly strengthen our 5-path program of clinical trials.”

Prof. Blaise was excited by the scope of work ahead:
“I really look forward to working with the clinical advisory board at Race on the development of new, improved combination regimens based on bisantrene for both children with high-risk acute leukaemia, and adults with leukaemia and solid tumours. This program promises to become more efficient, yet less toxic than previously available treatments, and the patients’ fight against cancer may now for the first time be relieved from the risk of suffering long-lasting and devastating heart failure as the price for successfully conquering a malignant disease.”

Detailed background Prof. Didier Blaise:

Prof. Blaise is Professor of Medicine at the Aix-Marseille University in Marseille, France and Chairman of the Marseille University Hematology Department at Institute Paoli Calmettes. He has been the leader of the Blood and Marrow Transplantation and Immune Cellular Therapy program at Institute Paoli Calmettes since 1991. This program is one of the most active in Europe, with more than 8800 transplants conducted. Prof. Blaise is also the program leader of the Transplant and Cellular Immunotherapy program in the INSERM, the Tumor Immunology team of the Cancer Research Center of Marseilles (CRCM), and the President of the Medical Council of Institute Paoli Calmettes in Marseilles.

In addition, Professor Blaise was a founding member and former President of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and is an active member of numerous international haematology and oncology scientific societies, notably EBMT, EHA, ASH, ASCO, ASTCT and ISEH.

Prof. Blaise has conducted numerous national and international clinical trials in the field of hematopoietic stem cell transplantation and oncology, the author or co-author of more than 500 peer reviewed papers, and the recipient of many national grants.

His research interests focus on clinical transplantation, dose intensity of conditioning regimens, immunomodulation after allogeneic transplantation, immunotherapy and cellular immunotherapy of hematologic malignancies and solid tumours, and the economic and social impact of innovation in these clinical areas.


  • Share this post

Previous Article Race raises A$1.8 million, appoints Non-Executive Chairman

Comments

Comments are closed.

© 2019 Race Oncology. Website By Multiplier